Fluconazole

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China

Retrieved on: 
Wednesday, February 7, 2024

DURHAM, N.C., Feb. 7, 2024 /PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC). VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.

Key Points: 
  • VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.
  • "The disease burden in China is significant, and access to VIVJOA provides health care providers and women suffering with severe VVC a new treatment option."
  • Vulvovaginal candidiasis is an exceedingly common mucosal infection usually caused by Candida albicans but can occasionally be caused by other Candida species or yeasts.
  • In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA (oteseconazole) Capsules as the first medication for Recurrent Vulvovaginal Candidiasis (RVVC, or chronic yeast infection).

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

Retrieved on: 
Wednesday, October 11, 2023

The abstract being presented highlights data regarding in vitro activity of taurolidine against the fungus Candida auris, an emerging cause of life-threatening bloodstream infections, with increasing resistance to common antifungal agents.

Key Points: 
  • The abstract being presented highlights data regarding in vitro activity of taurolidine against the fungus Candida auris, an emerging cause of life-threatening bloodstream infections, with increasing resistance to common antifungal agents.
  • Taurolidine exhibited in vitro antimicrobial activity against all C. auris strains and isolates regardless of geographic source, year of isolation, or clade.
  • There was no evidence that taurolidine activity was affected by resistance to amphotericin B or fluconazole.
  • The abstract is available through the IDWeek conference website.

Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

Retrieved on: 
Wednesday, October 11, 2023

This patient was treated under Matinas’ Expanded Access/Compassionate Use Program by Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.

Key Points: 
  • This patient was treated under Matinas’ Expanded Access/Compassionate Use Program by Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.
  • “We are thrilled with the positive clinical impact MAT2203 had on this extremely ill patient with limited treatment options,” said Dr. Miceli.
  • Treatment with MAT2203 led to complete resolution of his symptoms and improvement of his kidney function to baseline.
  • We are grateful to the participants in our Expanded Access program and to their physicians for recognizing the clinical potential of MAT2203 in treating a broad spectrum of invasive fungal infections.”
    MAT2203 is not yet licensed or approved anywhere globally.

Vulvovaginal Candidiasis Treatment Research Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 10, 2023

The increasing demand for vulvovaginal candidiasis treatment can be attributed to several key factors driving its growth.

Key Points: 
  • The increasing demand for vulvovaginal candidiasis treatment can be attributed to several key factors driving its growth.
  • Furthermore, the global population's growing awareness of the need for effective yet cost-efficient treatment options, particularly among the elderly demographic, has led to a surge in demand for vulvovaginal candidiasis treatment on a global scale.
  • The market's growth is further driven by the rising prevalence of acute vulvovaginal candidiasis infections among the global population, with an increasing number of research initiatives aimed at understanding the prevalence of conditions like recurrent vulvovaginal candidiasis (RVVC).
  • Company Profiles: Detailed analysis of the major companies present in Global Vulvovaginal Candidiasis Treatment Market.

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Retrieved on: 
Wednesday, August 30, 2023

Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market

Key Points: 
  • Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market
    WASHINGTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced the journal, New Microbes and New Infections , has published non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity, including against Candida spp.
  • in cell culture, and decreases fungal burden in the lungs in an invasive pulmonary model of Rhizopus in mice.
  • 60P was recently awarded a U.S. patent covering tafenoquine for treatment of COVID-19 and other lung infections.
  • “A substantial unmet need exists for clinical therapies that treat and prevent life-threatening fungal infections,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow.

Global Invasive Fungal Infections Market Report 2023: Increasing Invasive Fungal Infections with Life-threatening Conditions Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, May 29, 2023

However, there are also antibody molecules in early preclinical development, which are currently not on the market.

Key Points: 
  • However, there are also antibody molecules in early preclinical development, which are currently not on the market.
  • The increasing use of broad-spectrum antibiotics, the aging population, and the growing prevalence of immunocompromised patients are driving the growth of invasive candidiasis.
  • By Region: The report provides insight into the invasive fungal infections market based on the geographical operations, namely North America, Europe, Asia Pacific, and ROW.
  • The North American region has emerged as a dominant player in the invasive fungal infections market, owing to several key factors.

SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023

JERSEY CITY, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • JERSEY CITY, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced financial results for the first quarter ended March 31, 2023.
  • On March 30, 2023, SCYNEXIS announced that the Company has entered into an exclusive agreement with GSK to commercialize and further develop BREXAFEMME® (ibrexafungerp tablets) for all indications.
  • BREXAFEMME net sales were $1.1 million in first quarter 2023 and $0.7 million in Q1 2022.
  • Cash, cash equivalents and short-term investments totaled $54.8 million on March 31, 2023, compared to $73.5 million on December 31, 2022.

SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 31, 2023

GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.

Key Points: 
  • GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.
  • JERSEY CITY, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2022.
  • According to IQVIA data, there were 5,125 total prescriptions for BREXAFEMME written in Q4 2022, and more than 20,000 total prescriptions written in 2022.
  • The approval was based on positive results from the pivotal Phase 3 CANDLE study reported in February 2022.